Companies Learn

Company

Spyre Therapeutics Inc SYRE

Tracked across 1 disclosed holder on Protégé.

Held by these investors

Investor	% of portfolio	Value
Samlyn Capital	0.6%	$35.5M

Open the full company deep-dive →

Education only, not investment advice. 13F filings show long US-listed equity positions reported up to 45 days after quarter end; politicians' trades are disclosed dollar ranges under the STOCK Act; CEO trades come from SEC Form 4. Not affiliated with or endorsed by anyone shown.

Back to Protégé